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Abstract
Multiple myeloma remains an incurable disease. One of the major problems is that myeloma cells develop drug resistance upon interaction with bone marrow stromal cells.
In this study we examined the effects of macrophages (Mφ), a type of stromal cells, on myeloma cell survival and response to chemotherapy. We showed that Mφ, in particular tumor-associated Mφ, are a protector of myeloma cells. The protective effect was dependent upon direct contact between Mφ and myeloma cells. Mφ protected both myeloma cell lines and primary myeloma cells from spontaneous and chemotherapy drug-induced apoptosis by attenuating the activation and cleavage of caspase-dependent apoptotic signaling. These findings are clinically relevant, because we found that CD68 + Mφ heavily infiltrate the bone marrow of patients with myeloma but not the bone marrow of control patients. Thus, our results indicate that Mφ may contribute to myeloma cell survival and resistance to chemotherapeutic treatment in vivo.
Introduction
Multiple myeloma (MM) is a malignant B-cell tumor characterized by proliferation of monoclonal plasma cells in the bone marrow 1 . Although chemotherapy is the most effective treatment for MM at present time, myeloma cells often fail to respond to the drugs. Studies have shown that the response of myeloma cells to cytotoxic chemotherapeutics can be attenuated by the presence of bone marrow stromal cells 2, 3 .
However, the mechanisms of myeloma cell proliferation and failure to respond to chemotherapeutic drugs are not fully defined. To better understand the role of different stromal cell components in the bone marrow microenvironment, we examined the effects of macrophages (Mφ) on myeloma cell survival and response to chemotherapy in this study.
Materials and Methods

Myeloma cells, antibody, and reagents
Primary myeloma cells were isolated from bone marrow aspirates of myeloma patients.
IL-6 and M-CSF antibodies were purchased from R&D Systems (Minneapolis, MN).
Melphalan, dexamethasone, cytochalasin D, and FITC-labeled dextran were purchased from Sigma-Aldrich (St. Louis, MO). The study was approved by the Institutional Review Board at The University of Texas M. D. Anderson Cancer Center.
Generation of macrophages
Mononuclear cells from the blood of healthy donors were incubated in 12-well plates for 2 hours (h) at 37°C to remove non-adherent cells. The adherent monocytes were incubated for 7 days in medium with M-CSF 4 to become nMφ. nMφ were cultured for an additional 72 h with tumor-culture conditioning medium (TCCM) of myeloma cells 5 to generate tMφ. Mφ were also generated from blood monocytes of patients with MM in a 7-day culture with M-CSF and used in the experiments.
Apoptosis assay
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Annexin-V staining was used to detect apoptosis in myeloma cells as described previously 6 . To exclude apoptotic macrophages, cultured cells were stained with PEconjugated anti-CD138 antibody and FITC-conjugated Annexin V, and apoptotic myeloma cells were identified as CD138 + Annexin V + cells.
Immunohistochemistry analysis
Sections of bone marrow biopsies from MM and control patients were examined by immunohistochemistry staining as described previously 7 .
Results and Discussion
To evaluate the effect of Mφ on myeloma cells, we examined whether Mφ could protect myeloma cells from chemotherapy drug-induced apoptosis. As shown in Figure 1A , Figure 1D ). These results indicate that cell-cell contact plays a major role in Mφ-mediated protection of myeloma cell apoptosis.
Furthermore, we examined whether Mφ can also support primary myeloma cell survival.
Primary myeloma cells freshly isolated from patients with MM undergo apoptosis ex vivo in medium unless they are cocultured with stromal cells 8 . As shown in Figure 1E depicting the representative data obtained from experiments with samples from one out of four patients examined, approximately 50% and 80% of primary myeloma cells were apoptotic 24 h and 48 h, respectively, after isolation, whereas fewer than 20% of the cells were apoptotic when cocultured with tMφ. We also found that coculture with myeloma patients-derived Mφ significantly protected myeloma cell apoptosis induced by melphalan ( Figure 1F ). These results indicate that Mφ, especially tMφ, may be a protector of myeloma cell apoptosis. Studies have shown that tMφ are driven by tumor-derived cytokines to acquire a polarized type-2 phenotype, which differ in terms of receptor expression, effector function, and cytokine and chemokine production 9 .
To elucidate the mechanism underlying Mφ-mediated protection in myeloma cells, we examined apoptotic signaling pathways in myeloma cells. By using Western blot analysis, we showed that melphalan treatment activates and induces cleavage of caspase- Next we examined whether IL-6, one of the most important cytokines for myeloma growth and survival 10 , plays a role in Mφ-mediated protection of myeloma cell apoptosis. As shown in Figure 2B , the level of IL-6 was significantly higher in the supernatant of tMφ than that of nMφ or TCCM (P < 0.01). To examine the importance of IL-6 in tMφ-mediated protection, neutralizing antibody against IL-6 was used. As shown in Figure 2C , addition of anti-IL-6 specific antibody did not affect tMφ-mediated protection of myeloma cells from melphalan-induced apoptosis, indicating that IL-6 did not contribute to the protective effects of tMφ. It may be possible that the growth and anti-apoptotic signaling generated by cell-cell contact is stronger than those of IL-6
signaling. Further studies are warranted to elucidate the mechanisms. 
